🔎 Trials Near Me

Akèy › Limfòm Burkitt › Distrik Columbia

Etid klinik pou Limfòm Burkitt nan Distrik Columbia

5 etid pou Limfòm Burkitt ap chèche patisipan nan sit nan Distrik Columbia.

Vil nan Distrik Columbia

Tèks ofisyèl etid la (Anglè)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  • MedStar Georgetown University Hospital, Washington D.C.
  • Children's National Medical Center, Washington D.C.
Ap rekriteFaz 2
366 Days – 46 Years · Tout sèks · Mizajou Oct 2, 2026 · NCT06124157

Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

  • MedStar Georgetown University Hospital, Washington D.C.
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT03739814

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • Children's National Medical Center, Washington D.C.
Ap rekriteFaz 2
365 Days · Tout sèks · Mizajou Sep 25, 2026 · NCT06317662

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • Children's National Medical Center, Washington D.C.
Ap rekriteFaz 2
Laj 1 a 30 · Tout sèks · Mizajou Sep 1, 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • Children's National Medical Center, Washington D.C.
Ap rekriteFaz 3
365 Days – 25 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT03959085

Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.